Hematological and biochemical abnormalities among women with breast cancer
DOI:
https://doi.org/10.54361/LJMR.20.1.01Keywords:
Breast cancer, hematological parameters, biochemical parameters, and ageAbstract
Background: Breast cancer is a complex and heterogeneous disease characterized by the abnormal proliferation of breast tissue, leading to tumor formation. It is the most common cancer diagnosis among women worldwide. Assessment of hematological and biochemical parameters can predict the severity, mortality, and follow-up treatment in women with breast cancer. The aim: The study aimed to evaluate hematological and biochemical parameters as useful markers among patients with breast cancer compared to healthy individuals. Methods: A total of 124 women diagnosed with breast cancer attended The Department of National Cancer Institute Sabratha (NCI), from November 2024 to March 2025, and 50 healthy controls from The Libyan Medical Centre at Zawia city were also involved in this study. Demographic and clinical data, including complete blood count, liver function, and kidney function, were obtained from these patients. Results: A significant decrease (P< 0.001) was observed in patients in terms of RBC HGB, HCT, MCV, and MCHC. On the other hand, platelet count (PLT) and lymphocytes were significantly higher in the patient groups than in controls (P<0.001 and P<0.5), respectively. Glucose and sodium levels were significantly lower in breast cancer patients (P 0.013 and P>0.001, respectively.
Conclusion: Routine blood testing represents one of the most accessible and essential diagnostic tools. Hematological and biochemical parameters may serve as valuable indicators to differentiate breast cancer patients from healthy individuals.
Downloads
References
1. Madhu, Y., Jain, S., Jain, P., Kashyap, N., Mangalhara, K. C., & Jain, B. P. Hematological and Biochemical Serum Markers in Breast Cancer: Diagnostic, Therapeutic, and Prognostic Significance. Exploratory Research and Hypothesis in Medicine. 2025; 10(4).
2. Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, et al. Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. Journal of the National Cancer Center. 2025; 5(3):287–296.
3. Obeagu, E. I., & Obeagu, G. U. (. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024; 103(3), e36905.
4. Løyland, B., Sandbekken, I. H., Grov, E. K., & Utne, I. Causes and Risk Factors of Breast Cancer, What Do We Know for Sure? An Evidence Synthesis of Systematic Reviews and Meta-Analyses. Cancers. 2024; 16(8),
5. Golubnitschaja, O.; Debald, M.; Yeghiazaryan, K.; Kuhn, W.; Pešta, M.; Costigliola, V.; Grech, G. Breast cancer epidemic in the early twenty-first century: Evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biology journal. 2016; 37, 12941–12957
6. Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, et al. Hematological predictive markers for recurrent or metastatic squa mous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Medicine. 2020;9(14):5015 5024.
7. Lin, J., Tu, R., & Lu, Z. E. Prediabetes and the risk of breast cancer: a meta-analysis. Frontiers in Oncology. 2023; 13, 1238845.
8. Saroosh, R., Ahmad, N., Israr, B., Nazir, A., Itrat, N., & Ahmad, A. M. R. Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey. BMC cancer. 2025; 25(1), 1276.
9. Naif, N. H., Oudah, H. A., & Aluloom, Y. J. B. Biochemical alterations in cancer: A clinical chemistry perspective on tumor pathogenesis. International Journal of Chemical and Biological Sciences. 2024; 6(2B), 122–132.
10. Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., & Liu, P. Prognostic value of PLR in various cancers: a meta-analysis. PloS one. 2014; 9(6), e101119.
11. Gusbi, E., Al-Mabrouk, A., & El-Fituri, O. Breast cancer in the western part of Libya: Pattern and management (2003–2018). Libyan Journal of Medical Sciences. 2020; 4(2), 52–59.
12. Najjar, H., & Easson, A. Age at diagnosis of breast cancer in Arab nations. International Journal of Surgery. 2010; 8(6), 448–452.
13. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024; 74(1), 5–29.
14. Surakasula, A., Katuri, L., & Rao, C. Risk factors for breast cancer in postmenopausal women. Journal of Women’s Health and Cancer Research. 2014. 6(3), 101–108.
15. Borghesan, D. H. P., Dell’Agnolo, C. M., Gravena, A. A. F., Demitto, M. O., Lopes, T. C. R., Carvalho, M. D. B., & Pelloso, S. M. Risk factors for breast cancer in postmenopausal women in Brazil: a case-control study. Asian Pacific Journal of Cancer Prevention. 2016;17(7), 3587–3593.
16. Bodalal, Z., Bendardaf, R., & Ambarek, M. Risk factors for breast cancer in Benghazi, Libya: A case-control study. International Journal of Surgery and Medicine Research. 2014;4(1), 112–118.
17. Saadatmand, S., Bretveld, R., Siesling, S., & Tilanus-Linthorst, M. M. A. Breast cancer risk associated with family history by relative’s age at diagnosis: A population-based cohort study. JAMA Internal Medicine. 2022. 182(4), 400–408.
18. Wang, H., Lee, C., & Zhang, X. Family history and breast cancer risk among Asian women: A systematic review and meta-analysis. BMC Medicine. 2023; 21(1), 123.
19. Mane, N., Fouqani, A., Mrah, S., Omari, M., Bouaddi, O., Faure, E., & Khalis, M. Obesity and Risk of Pre-and Postmenopausal Breast Cancer in Africa: A Systematic Review. Current Oncology. 2025; 32(3), 167.
20. El-Hattab, O., Soliman, A. S., & Khaled, H. Obesity and breast cancer risk among Egyptian women: A hospital-based case-control study. Asian Pacific Journal of Cancer Prevention. 2021; 22(3), 841–848.
21. Al-Tamimi, D. M., Shawarby, M. A., Ahmed, A., Hassan, S. H., & AlOdaini, A. A. Protein expression profile and prevalence pattern of the molecular classes of breast cancer—a Saudi population-based study. BMC Cancer. 2019; 19(1), 121.
22. Chinedu-Madu Jane, U., Onyenze Chimdiya, A., & Aloy-Amadi Oluchi, C. Assessment of Red Blood Cell Count and Red Cell Indices in Patients Diagnosed with Breast Cancer at Federal Teaching hospital, Owerri Nigeria. International Journal of clinical and Medical Case Reports. 2025; 4(3).
23. Khan, S., Khoso, S. A., Memon, S., Adeel, A., & Nabi, G.. Study of some Hematological parameters as Biomarker for breast Cancer population of Sindh. Sindh University Research Journal-SURJ (Science Series). 2017; 49(1).
24. Beresford M. J., R Burcombe, M. L. Ah-See D. Stott, A: Pre-treatment haemoglobin levels and the prediction of response to neoadjuvantchemot- herapy in breast cancer. Clinical Oncology Journal. 2006; 18:453-458
25. Taucher, S., Salat, A., Gnant, M., Kwasny, W., Mlineritsch, B., Menzel, R. C., & Jakesz, R. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thrombosis and haemostasis. 2003; 89(06), 1098-1106.
26. Liu S, Fang J, Jiao D, Liu Z. Elevated Platelet Count Predicts Poor Prognosis in Breast Cancer Patients with Supraclavicular Lymph Node Metastasis. Cancer Management and Research. 2020; 20; 12:6069.
27. Shin, E., & Koo, J. S. Glucose metabolism and glucose transporters in breast cancer. Frontiers in cell and developmental biology. 2021; 9, 728759.
28. Bosso, M., Haddad, D., Al Madhoun, A., & Al-Mulla, F. Targeting the metabolic paradigms in cancer and diabetes. Biomedicines. 2024;12(1), 211.
29. Fibbi, B., Marroncini, G., Naldi, L., Anceschi, C., Errico, A., Norello, D., & Peri, A. (2023). Hyponatremia and cancer: from bedside to benchside. Cancers, 15(4), 1197.
30. Castillo, J. J., & Cohen, H. J. Diagnosis and management of hyponatremia in cancer patients. Journal of Supportive Oncology. 2012; 10(3), 98–105. (Review).
31. Al-Saeedi, T. K. J., Alsamarai, A. T. S., & Al-Sammarraie, A. Z Evaluation of CA15-3, blood urea and creatinine in breast cancer patients. Iraqi National Journal of Chemistry. 2023; 23(1).
32. Abbasi, N. A. Surveillance of Blood Chemistry in Breast Cancer Patients Belonging to Punjab, Pakistan. Pakistan Journal of Science. 2023;75(3).
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fathia G. Jaat, Marwa F Alqallali, Nadia. M. Kermani, Sedik. A. Abokdeer, Omar. A. Murgham (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
